Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP1585 Long-term Study in CKD Patients With Hyperphosphatemia
NCT01742611Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Mar 2013
- Primary completion
- Apr 2015
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of bixalomer in hyperphosphatemia, sponsored by Astellas Pharma. Primary endpoint: Serum phosphorus levels at 48 weeks. Started Mar 2013; status: completed.
02
Drugs
bixalomer
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on NCT01742611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01742611.